Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors

Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in... This phase 1b/2a nonrandomized clinical trial assesses combination of a type II KIT inhibitor with a conformation-complementary, active-state (type I) KIT inhibitor and broad mutation coverage and global disease control. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/american-medical-association/association-of-combination-of-conformation-specific-kit-inhibitors-Iy0Mo4qvFo
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2021.2086
Publisher site
See Article on Publisher Site

Abstract

This phase 1b/2a nonrandomized clinical trial assesses combination of a type II KIT inhibitor with a conformation-complementary, active-state (type I) KIT inhibitor and broad mutation coverage and global disease control.

Journal

JAMA OncologyAmerican Medical Association

Published: Sep 8, 2021

References